We were founded in 1982 as a small, family-run business specialising in niche therapies. Following a period of successful growth, Britannia was acquired by STADA in 2007, and has been their global speciality pharmaceutical centre of excellence ever since.
One of our core products, Apomorphine Hydrochloride, was developed in association with leading UK neurology centres and registered in the UK in 1994, and in the US in 2004. This product has been successfully introduced into over 30 countries globally, with more launches scheduled.
We continue to redefine and innovate drug delivery methods for Parkinson’s and other disorders – and lead the way in innovative technology and patient support.